Compare HOMB & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOMB | ALKS |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.8B |
| IPO Year | 2006 | 1991 |
| Metric | HOMB | ALKS |
|---|---|---|
| Price | $28.38 | $29.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $32.40 | ★ $42.85 |
| AVG Volume (30 Days) | 882.9K | ★ 2.5M |
| Earning Date | 01-14-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 18.95 | 2.44 |
| EPS | ★ 2.30 | 2.02 |
| Revenue | $1,042,417,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $13.21 | N/A |
| Revenue Next Year | $3.01 | $24.22 |
| P/E Ratio | ★ $12.35 | $14.67 |
| Revenue Growth | ★ 7.75 | 1.08 |
| 52 Week Low | $24.22 | $25.17 |
| 52 Week High | $31.57 | $36.45 |
| Indicator | HOMB | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 48.29 |
| Support Level | $27.80 | $28.96 |
| Resistance Level | $28.65 | $30.10 |
| Average True Range (ATR) | 0.56 | 0.92 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 89.10 | 68.21 |
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality and a solid balance sheet. The bank's main source of net revenue is net interest income.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.